MAIT cells have also demonstrated the ability to effectively lyse GBM cells in an MR1-dependent manner at higher effector-to-target ratios, underscoring their potential to target gliomas via MR1-antigen recognition and highlighting new avenues for glioma immunotherapy. The gene discussed is MR1; the disease is glioblastoma.